NEW YORK, NY --(Marketwired - June 03, 2016) - Lion Biotechnologies, Inc. (
A live webcast of the presentation will be available by visiting the Investors section of Lion Biotechnologies' website at http://ir.lbio.com/ . A replay of the webcast will be archived on Lion Biotechnologies' website for 30 days following the presentation.
About Lion Biotechnologies Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com .
Forward-Looking Statements This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including risks related to the Company's ability to complete its ongoing Phase 2 study of LN-144 and the other risks and uncertainties described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact: Sarah McCabe Stern Investor Relations, Inc. Office: 212-362-1200 Media Relations Contact: Jody LoMenzo inVentiv Health Public Relations Office: 212-364-0458 Mobile: 646-866-1721